Furthermore, BTG2 strongly induces G2/M phase arrest in U937 myelomonocytic leukemia (p53 null) and Huh7 (p53 mutant) hepatoma cells [22], therefore, we earlier suggested BTG2 as a pan-cell cycle inhibitor independent of p53 and pRB activities via interaction with Pin1 in response to EGF stimulation [23]. The gene discussed is TP53; the disease is hepatocellular carcinoma.